Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kiromic Biopharma Inc
(NQ:
KRBP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kiromic Biopharma Inc
< Previous
1
2
3
Next >
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
May 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
May 20, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
April 24, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
April 02, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
March 19, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
March 08, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
March 05, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
March 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
Live and Archived Fireside Chat Available at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
February 14, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
January 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
January 05, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
December 14, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Uplisting to OTCQB Market
November 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
November 09, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
October 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
September 13, 2023
From
Kiromic BioPharma
Via
Business Wire
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
May 01, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
April 03, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Reverse Stock Split
March 10, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
February 28, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
February 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma CEO Issues Letter to Stockholders
February 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
NASDAQ:KRBP Long Term Investor Alert: Investigation over Possible Wrongdoing at Kiromic BioPharma, Inc.
November 09, 2022
San Diego, CA -- (SBWIRE) -- 11/09/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Kiromic BioPharma, Inc..
Via
SBWire
Kiromic BioPharma Arranges Up to $10 Million Financing
October 27, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
October 06, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate
October 03, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, Kiromic, and LifeStance and Encourages Investors to Contact the Firm
October 02, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.